GeneDx Holdings (WGS) Other financing activities (2020 - 2026)

GeneDx Holdings (WGS) has reported Other financing activities for 7 consecutive years, with -$95.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities fell 74278.91% year-over-year to -$95.2 million in Q2 2026; TTM through Jun 2026 was $34.7 million, a 42.21% decrease from a year earlier, with the FY2025 full-year figure at $46.7 million, changed 0.45% from the prior year.
• Other financing activities was -$95.2 million for Q2 2026 at GeneDx Holdings, down from $97.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $197.0 million in Q2 2022 and troughed at -$95.2 million in Q2 2026.
• A 5-year average of $29.0 million and a median of $11.8 million in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities surged 57791.67% in 2025 and slumped 74278.91% in 2026, its largest moves.
• Over 5 years, Other financing activities stood at -$53000.0 in 2022, then surged by 14369.81% to $7.6 million in 2023, then surged by 321.88% to $31.9 million in 2024, then slumped by 33.76% to $21.1 million in 2025, then slumped by 550.44% to -$95.2 million in 2026.
• The last three Other financing activities figures came in at -$95.2 million (Q2 2026), $97.0 million (Q1 2026), and $21.1 million (Q4 2025), per Business Quant data.